In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014–2015
Copyright policy )In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014–2015
Enmetazobactam, formerly AAI101, is a novel penicillanic acid sulfone extended-spectrum β-lactamase (ESBL) inhibitor. The combination of enmetazobactam with cefepime has entered clinical trials to assess safety and efficacy in patients with complicated urinary tract infections.
Cross Infection, Tazobactam, Microbial Sensitivity Tests, Triazoles, Ceftazidime, Hospitals, United States, Epidemiology and Surveillance, Anti-Bacterial Agents, Cephalosporins, Europe, Drug Combinations, Enterobacteriaceae, Drug Resistance, Bacterial, Gram-Negative Bacteria, Pseudomonas aeruginosa, Humans, Cefepime, Gram-Negative Bacterial Infections, Azabicyclo Compounds
Cross Infection, Tazobactam, Microbial Sensitivity Tests, Triazoles, Ceftazidime, Hospitals, United States, Epidemiology and Surveillance, Anti-Bacterial Agents, Cephalosporins, Europe, Drug Combinations, Enterobacteriaceae, Drug Resistance, Bacterial, Gram-Negative Bacteria, Pseudomonas aeruginosa, Humans, Cefepime, Gram-Negative Bacterial Infections, Azabicyclo Compounds
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).61 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!